![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Zykadia Wins FDA Priority Review in First-Line Metastatic NSCLC
Zykadia Wins FDA Priority Review in First-Line Metastatic NSCLC
March 3, 2017
Novartis has gained FDA Priority Review for the expanded use of Zykadia as a first-line treatment for patients with metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase-positive as detected by an FDA-approved test.
The FDA also granted a Breakthrough Therapy designation to Zykadia for the first-line treatment of patients with ALK+ metastatic NSCLC with brain metastases.
Upcoming Events
-
21Oct